engleski

Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes

in people with T2D, the coexistence of microvascular disease in the setting of established macrovascular disease is associated with increased cardiovascular risk, including— notably—HHF, which has hitherto been underappreciated. The cardiovascular benefit of empagliflozin in this population was consistent with its effects in people without microvascular disease. These findings from a large modern CVOT add to the limited prospective data on the effect of microvascular disease on cardiovascular and HF outcomes in people with T2D.

type 2 diabetes ; microvascular disease ; macrovascular disease ; cardiovascular benefit ; empagliflozin

nije evidentirano